Shares of OncoMed Pharmaceuticals fell after the company announced that Celgene walked away from a deal to license the bispecific antibody navicixizumab.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Augmented reality (AR) gained widespread attention the summer of 2016 with the addictive game Pokémon Go. But these days, AR is not just for fun. This disruptive technology is expected to drive significant changes to businesses across many industries because of its ability to combine the virtual and physical worlds.
Augmented reality (AR) and virtual reality (VR) have experienced incredible growth since 2013, when the first Oculus Rift VR headset hit the market and provided a whole new sense of what was possible.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Pharma marketers must listen to their customers and find ways to smooth the patient journey if they are to create effective customer experiences and create loyalty beyond the first prescription.
Consumer/Patient Experience Special Feature: Digital therapeutics – Improving the patient experience at scale
It’s no surprise that the patient experience with the healthcare system often leads to frustration and despair. With chronic disease affecting around 50 percent of the U.S. population, it puts into perspective the sheer volume of patient experiences that are being generated each day and the magnitude of the problems that need solving. The high cost of therapies, the long wait to see a physician, the administrative burden of getting a prior authorization…the list goes on. But the day is coming, and in some cases it’s already here, where a patient could have a robust health system right in their pocket.
Consumer/Patient Experience Special Feature: Masters Of The Pharma Universe: 4 Databases Every Digital Marketer Must Know
Nearly two-thirds of U.S. senior business decision-makers rank big data/analytics first among the technologies necessary for enhancing the customer experience. A similar number put “improving data analysis capabilities” at the top of their priorities.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
Amicus Therapeutics inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.
Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.
Elanco Animal Health’s shares climbed 36 percent in their stock market debut, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.
Insurance Commissioner Dave Jones filed a complaint on behalf of the State of California against AbbVie Inc., alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe the company’s blockbuster medicine Humira.
U.S. biotechnology company Clovis Oncology Inc., Chief Executive Patrick Mahaffy, and former CFO Erle Mast will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said.
A second former GlaxoSmithKline scientist pled guilty to stealing trade secrets as part of a scheme to benefit a startup China-based pharmaceutical company he helped establish.
Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.
Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.
Health insurer Cigna Corp.’s $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co. passed U.S. antitrust scrutiny, the companies said.
Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review
Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
Coca-Cola Co. is closely watching the growing marijuana-infused drinks market, responding to a media report that the world’s largest beverage maker was in talks with Canada’s Aurora Cannabis Inc.
Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.
If you are a clinical researcher or scientist, you are well-aware of the inefficiencies of current search processes that require hours of time wading through data to find hidden nuggets of valuable info.
Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.
Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, while several of the company’s key drugs are selling well.
Lisle, Ill.-based medtech company Endotronix Inc. secured $45 million in a Series D financing round.